Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• This summary is based on the review of 43 systematic review(s)/meta-analysis(es). ^[1-43]
• Hemoglobin A1C (HbA1c) Reduction: Ertugliflozin showed a significant reduction in HbA1c levels compared to placebo, with a mean difference (MD) of -0.62% (95% confidence interval (CI) [-0.80, -0.44]) for 5 mg and -0.69% (95% CI [-0.91, -0.47]) for 15 mg. Reductions were comparable to other sodium-glucose cotransporter-2 (SGLT2) inhibitors.
• Fasting Plasma Glucose (FPG): Significant reductions in FPG were observed with both 5 mg and 15 mg doses of ertugliflozin compared to placebo and other hypoglycemic agents.
• Body Weight Reduction: Ertugliflozin significantly reduced body weight, with more pronounced effects at the 15 mg dose. Its efficacy in weight reduction was similar to other SGLT2 inhibitors.
• Cardiovascular Outcomes: Ertugliflozin reduced hospitalizations for heart failure (hazard ratio (HR) 0.70, 95% CI 0.54-0.90) but had a borderline effect on major adverse cardiovascular events (MACEs), with slightly less efficacy compared to empagliflozin and canagliflozin.
• Adverse Events: Ertugliflozin's adverse event profile was comparable to placebo, except for a higher incidence of genital mycotic infections, particularly in female patients, with consistent findings across doses and populations.
• Other Safety Concerns: There were no significant differences in the risk of serious adverse events, including hypoglycemia, urinary tract infections, acute kidney injury, fractures, or cardiovascular adverse events, compared to placebo.
• There is no population types or subgroups information available in the reviewed studies.